Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

June 11, 2024

https://www.globenewswire.com/news-release/2024/06/11/2896641/0/en/Akero-Therapeutics-Announces-Initiation-of-Phase-3-SYNCHRONY-Outcomes-Trial-of-Efruxifermin-in-Patients-with-Compensated-Cirrhosis-F4-Due-to-MASH.html

SOUTH SAN FRANCISCO, Calif., June 11, 2024 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced initiation of the SYNCHRONY Outcomes study, a Phase 3 trial evaluating the efficacy and safety of efruxifermin (EFX) in patients with compensated cirrhosis, fibrosis stage 4 (F4) due to metabolic dysfunction-associated steatohepatitis (MASH).

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.